Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

In recent months, Rigel Pharmaceuticals (NASDAQ: RIGL ) has surged by nearly 50.1% since July. RIGL's strength lies in its successful execution, innovative portfolio, strategic partnerships, and continued research pipeline progress. Its main value drivers are the FDA-approved drugs Tavalisse, Rezlidhia, and Gavreto. These My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer ...